The market has been high on Celsion Corporation (CLSN) stock recently. CLSN gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.
Celsion Corporation has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CLSN!
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With CLSN Stock Today?
Celsion Corporation (CLSN) stock has risen 15.54% while the S&P 500 is lower by -1.05% as of 11:58 AM on Wednesday, May 20. CLSN has gained $0.23 from the previous closing price of $1.48 on volume of 2,877,214 shares. Over the past year the S&P 500 is up 2.91% while CLSN is lower by -16.59%. CLSN lost -$0.77 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Celsion Corporation click here.
More About Celsion Corporation
Celsion Corp is active in the biotechnology market. The company acts as a drug developer with product candidates like ThermoDox, a heat-activated liposomal encapsulation of doxorubicin. It is in Phase III clinical trial for the treatment of primary liver cancer and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer. Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.
